Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Authors: Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim, Byoung Chul Cho, Radj Gervais, José Luis Perez‐Gracia, Ji‐Youn Han, Margarita Majem, Martin Förster, I. Monnet, Silvia Novello, Matthew A. Gubens, Michael Boyer, Wu‐Chou Su, Ayman Samkari, Erin Jensen, Julie Kobie, Bilal Piperdi, Paul Baas - Journal of Thoracic Oncology 2021 cited by 312